COMP <GO>

DRUG vs PBYI // OPERATING MARGIN

Bright Minds Biosciences Inc. (NASDAQ) VS. Puma Biotechnology Inc (NASDAQ) • 15-METRIC TALLY: DRUG 1 — PBYI 1

■ METRIC PARITY

LAST: $56.69 (+2.48%) • MKT CAP: $556.7M

operating-margins

—

LAST: $10.54 (-0.75%) • MKT CAP: $544.1M

operating-margins

16.30%

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DRUG VS. PBYI) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	DRUG	PBYI	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	74.50%	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	—	29.30%	—	TIE	/roic <GO>
EV/EBITDA & P/E Valuation	—	13.8x	—	TIE	/valuation <GO>
Free Cash Flow Yield	—	7.67%	—	TIE	/fcf-yield <GO>
Operating Margin ACTIVE	—	16.30%	—	TIE	/operating-margins <GO>
Net Profit Margin	—	13.60%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	-0.90%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	0.00%	0.00	TIE	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	0.20	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	—	8/9	—	TIE	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	50.3	52.9	-2.61	PBYI	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	16.3x	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$556.7M	$544.1M	$12.6M	DRUG	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	DRUG REV	PBYI REV	DRUG GROSS %	PBYI GROSS %	DRUG FCF	PBYI FCF
FY 2025	—	$228.4M	—	74.5%	—	$41.7M
FY 2024	—	$230.5M	—	72.1%	—	$38.9M
FY 2023	—	$235.6M	—	—	—	$27.0M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

DRUG // BETA —

PBYI // BETA —